Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Carcinoma, Non-Small-Cell Lung 7Carcinoma, Renal Cell 4Lung Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Carcinoma, Hepatocellular 3Ovarian Neoplasms 2Neoplasms 2Neoplasm, Residual 2NSCLC 2Leukemia, Myeloid, Chronic-Phase 2Kidney Neoplasms 2Uterine Cervical Neoplasms 1Thoracic Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Respiratory Tract Neoplasms 1Respiratory Tract Diseases 1Recurrence 1Pleural Neoplasms 1Pleural Effusion, Malignant 1Pleural Effusion 1Pleural Diseases 1Philadelphia Chromosome 1Neoplasms by Site 1Lung Diseases 1Liver Neoplasms 1Leukemia, Biphenotypic, Acute 1Leukemia 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Temozolomide 162Radiosurgery 115Radiotherapy 100Bevacizumab 96Magnetic Resonance Spectroscopy 65Carboplatin 48Etoposide 34pembrolizumab 33Surgical Procedures, Operative 33Irinotecan 33Nivolumab 32Cyclophosphamide 32Erlotinib Hydrochloride 31Radiation 30Carmustine 28Cisplatin 25Lomustine 24Trastuzumab 23Ipilimumab 23Filgrastim 23Vincristine 20Mental Status and Dementia Tests 20Aminolevulinic Acid 19Topotecan 18Pemetrexed 18Capecitabine 18Specimen Handling 17Sorafenib 15Radiotherapy, Intensity-Modulated 15Imatinib Mesylate 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Brain Neoplasms × Tyrosine Kinase Inhibitors × Clear all
NCT04760431 2021-06-02

TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Unknown
120 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡